GlassScriptPhysician profile
Sabrina D Lambert
NPI 1750749065
$8,923.82
in general payments reported to CMS, 2019-2025
33 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $711 · 2022: $1,619 · 2023: $1,942 · 2024: $2,439 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,492 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,491.52 |
| Education | $101.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,457.95 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,064.71 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $998.30 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $570.26 | 2021-2025 | |
| Grifols USA, LLC | $528.35 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $495.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $469.58 | 2021-2025 | Aralast, Glassia |
| Harmony Biosciences LLC | $358.41 | 2023-2025 | Wakix |
| Mylan Specialty L.P. | $350.55 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $228.53 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $164.93 | 2022-2023 | Xolair |
| Abbott Laboratories | $140.83 | 2023 | Cardiomems |
| Insmed, INC. | $119.42 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $117.18 | 2024-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $113.43 | 2022-2023 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $103.13 | 2025 | Ohtuvayre |
| Amgen INC. | $101.10 | 2022-2025 | Tezspire |
| Baxter Healthcare | $69.77 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Novo Nordisk INC | $57.50 | 2024 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $47.38 | 2023 | Uptravi |
| Inogen, INC. | $46.18 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pulmonx Corporation | $45.68 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $44.40 | 2024-2025 | Verquvo, Zerbaxa |
| Viatris Specialty LLC | $43.29 | 2025 | Yupelri |
| Philips North America LLC | $34.99 | 2025 | Vest Therapy Und |
| Abbvie INC. | $25.28 | 2023 | |
| Idorsia Pharmaceuticals US INC | $22.37 | 2025 | Quviviq |
| Csl Behring | $21.67 | 2025 | Hizentra |
| Electromed, INC. | $20.15 | 2022 | |
| Covis Pharma Gmbh | $16.92 | 2022 | |
| Allergan, INC. | $16.91 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.94 | 2022 | |
| Lilly USA, LLC | $14.47 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.